相似文献
1
Cardiac function and disease: emerging role of small ubiquitin-related modifier.
Wiley Interdiscip Rev Syst Biol Med. 2011 Jul-Aug;3(4):446-57. doi: 10.1002/wsbm.130. Epub 2010 Dec 31.
2
SUMO conjugation and cardiovascular development.
Front Biosci (Landmark Ed). 2009 Jan 1;14(4):1219-29. doi: 10.2741/3304.
3
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition.
Nat Rev Mol Cell Biol. 2010 Dec;11(12):861-71. doi: 10.1038/nrm3011.
4
Identification of biochemically distinct properties of the small ubiquitin-related modifier (SUMO) conjugation pathway in Plasmodium falciparum.
J Biol Chem. 2013 Sep 27;288(39):27724-36. doi: 10.1074/jbc.M113.498410. Epub 2013 Aug 13.
5
Modification of cardiac transcription factor Gata6 by SUMO.
Biochimie. 2020 Mar;170:212-218. doi: 10.1016/j.biochi.2020.01.014. Epub 2020 Feb 1.
6
System-wide Analysis of SUMOylation Dynamics in Response to Replication Stress Reveals Novel Small Ubiquitin-like Modified Target Proteins and Acceptor Lysines Relevant for Genome Stability.
Mol Cell Proteomics. 2015 May;14(5):1419-34. doi: 10.1074/mcp.O114.044792. Epub 2015 Mar 9.
7
Mechanisms, regulation and consequences of protein SUMOylation.
Biochem J. 2010 May 13;428(2):133-45. doi: 10.1042/BJ20100158.
8
Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
J Biol Chem. 2017 Sep 15;292(37):15340-15351. doi: 10.1074/jbc.M117.794255. Epub 2017 Aug 7.
9
Protein modification by SUMO.
Annu Rev Biochem. 2004;73:355-82. doi: 10.1146/annurev.biochem.73.011303.074118.
10
Molecular mechanisms in SUMO conjugation.
Biochem Soc Trans. 2020 Feb 28;48(1):123-135. doi: 10.1042/BST20190357.
引用本文的文献
1
The multifaceted nature of SUMOylation in heart disease and its therapeutic potential.
Mol Cell Biochem. 2025 Apr 27. doi: 10.1007/s11010-025-05286-z.
2
Sumoylation-deficient phosphoglycerate mutase 2 impairs myogenic differentiation.
Front Cell Dev Biol. 2022 Dec 14;10:1052363. doi: 10.3389/fcell.2022.1052363. eCollection 2022.
3
SUMOylation does not affect cardiac troponin I stability but alters indirectly the development of force in response to Ca.
FEBS J. 2022 Oct;289(20):6267-6285. doi: 10.1111/febs.16537. Epub 2022 Jun 8.
4
Identification of Natural Products as SENP2 Inhibitors for Targeted Therapy in Heart Failure.
Front Pharmacol. 2022 Apr 1;13:817990. doi: 10.3389/fphar.2022.817990. eCollection 2022.
5
Silencing SUMO2 promotes protection against degradation and apoptosis of nucleus pulposus cells through p53 signaling pathway in intervertebral disc degeneration.
Biosci Rep. 2018 Jun 29;38(3). doi: 10.1042/BSR20171523.
6
A Proteomic Approach to Identify Alterations in the Small Ubiquitin-like Modifier (SUMO) Network during Controlled Mechanical Ventilation in Rat Diaphragm Muscle.
Mol Cell Proteomics. 2017 Jun;16(6):1081-1097. doi: 10.1074/mcp.M116.066159. Epub 2017 Apr 3.
7
Sumoylation-independent activation of Calcineurin-NFAT-signaling via SUMO2 mediates cardiomyocyte hypertrophy.
Sci Rep. 2016 Oct 21;6:35758. doi: 10.1038/srep35758.
8
UBC9-Mediated Sumoylation Favorably Impacts Cardiac Function in Compromised Hearts.
Circ Res. 2016 Jun 10;118(12):1894-905. doi: 10.1161/CIRCRESAHA.115.308268. Epub 2016 May 3.
9
Post-translational Modifications in Heart Failure: Small Changes, Big Impact.
Heart Lung Circ. 2016 Apr;25(4):319-24. doi: 10.1016/j.hlc.2015.11.008. Epub 2015 Dec 4.
10
Neuronal SUMOylation: mechanisms, physiology, and roles in neuronal dysfunction.
Physiol Rev. 2014 Oct;94(4):1249-85. doi: 10.1152/physrev.00008.2014.
本文引用的文献
1
Sumoylation and regulation of cardiac gene expression.
Circ Res. 2010 Jul 9;107(1):19-29. doi: 10.1161/CIRCRESAHA.110.220491.
2
Elg1, an alternative subunit of the RFC clamp loader, preferentially interacts with SUMOylated PCNA.
EMBO J. 2010 Aug 4;29(15):2611-22. doi: 10.1038/emboj.2010.128. Epub 2010 Jun 22.
3
Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease.
Circ Cardiovasc Genet. 2010 Aug;3(4):374-85. doi: 10.1161/CIRCGENETICS.109.930867. Epub 2010 Jun 19.
4
Lamin A/C-related cardiac disease and pregnancy.
Eur J Heart Fail. 2010 Jun;12(6):532-4. doi: 10.1093/eurjhf/hfq081.
5
Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9.
J Biol Chem. 2010 Jul 2;285(27):20428-32. doi: 10.1074/jbc.C110.127191. Epub 2010 Apr 27.
6
SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development.
Mol Cell. 2010 Apr 23;38(2):191-201. doi: 10.1016/j.molcel.2010.03.005.
7
PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.
PPAR Res. 2009;2009:952734. doi: 10.1155/2009/952734. Epub 2010 Mar 16.
8
N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.
J Cell Sci. 2010 Apr 15;123(Pt 8):1227-34. doi: 10.1242/jcs.060160. Epub 2010 Mar 16.
9
Ubiquitylation and SUMOylation of cardiac ion channels.
J Cardiovasc Pharmacol. 2010 Jul;56(1):22-8. doi: 10.1097/FJC.0b013e3181daaff9.
10
ISG15 and immune diseases.
Biochim Biophys Acta. 2010 May;1802(5):485-96. doi: 10.1016/j.bbadis.2010.02.006. Epub 2010 Feb 12.
Zotero 插件